By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
ScienceabodeScienceabode
  • Home
  • News & Perspective
    News & PerspectiveShow More
    Microorganism that causes rare but severe eye infections detected in NSW coastal areas
    By Admin
    Scientists identify common cause of gastro in young children and adults over 50 years old
    By admin
    AI reveals hidden traits about our planet’s flora to help save species
    By admin
    Eye drops slow nearsightedness progression in kids, study finds
    By admin
    Using AI to create better, more potent medicines
    By admin
  • Latest News
    Latest NewsShow More
    Researchers develop new robot medics for places doctors are unable to be
    By Admin
    Even thinking about marriage gets young people to straighten up
    By admin
    Study: People tend to locate the self in the brain or the heart – and it affects their judgments and decisions
    By admin
    UCLA patient is first to receive successful heart transplant after using experimental 50cc Total Artificial Heart
    By admin
    Via Dying Cells, UVA Finds Potential Way to Control Cholesterol Levels
    By admin
  • Health
    Health
    The World Health Organization defines health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.”…
    Show More
    Top News
    Researchers design machine learning models to better predict adolescent suicide and self-harm risk
    September 11, 2023
    Scientists identify evolutionary gateway helping pneumonia bacteria become resistant to antibiotics   
    October 3, 2023
    New research indicates some people may be physically unable to use police breathalysers
    October 3, 2023
    Latest News
    Game-Changer in Emergency Medicine: New AI Test Flags Sepsis Hours Before Symptoms Worsen
    June 4, 2025
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    June 3, 2025
    Medical Milestone: Surgeons Perform First-Ever Human Bladder Transplant
    May 20, 2025
    A Downside of Taurine: It Drives Leukemia Growth
    May 19, 2025
  • Environment
    EnvironmentShow More
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    By Admin
    Arsenic exposure linked to faster onset of diabetes in south Texas population 
    By Admin
    Antarctica vulnerable to invasive species hitching rides on plastic and organic debris
    By Admin
    New substrate material for flexible electronics could help combat e-waste
    By Admin
    Bacteria ‘nanowires’ could help scientists develop green electronics
    By Admin
  • Infomation
    • Pricavy Policy
    • Terms of Service
  • Jobs
  • Application Submission
Notification Show More
Aa
ScienceabodeScienceabode
Aa
  • Home
  • Health
  • Anatomy
  • Jobs Portal
  • Application Submission
  • Categories
    • Health
    • Anatomy
    • Food & Diet
    • Beauty Lab
    • News & Perspective
    • Environment
  • More Foxiz
    • Blog Index
    • Sitemap
Follow US
Scienceabode > Blog > Health > Scientists Discover a New Signaling Pathway and Design a Novel Drug for Liver Fibrosis
Health

Scientists Discover a New Signaling Pathway and Design a Novel Drug for Liver Fibrosis

Admin
Last updated: 2024/05/02 at 6:08 PM
By Admin
Share
6 Min Read
SHARE

A healthy liver filters all the blood in your body, breaks down toxins and digests fats. It produces collagen to repair damaged cells when the liver is injured. However, a liver can produce too much collagen when an excess accumulation of fat causes chronic inflammation, a condition called metabolic dysfunction-associated steatohepatitis (MASH). In an advanced state, MASH can lead to cirrhosis, liver cancer and liver-related death.

The cells that produce collagen in livers are called hepatic stellate cells (HSC). In a new paper published in Cell Metabolism, scientists from the University of California San Diego investigated how these cells are activated. They found a three-component signaling pathway in the nucleus that functions according to a sort of police-controlling-the-police model.

Schematic of the TEAD 1 signaliing module that drives liver fibrosis. Credit: UC San Diego Health Sciences

- Advertisement -
MedBanner_Skyscraper_160x600_03/2018

In healthy livers, the first molecule in the pathway inhibits a second molecule, which inhibits the molecule that stimulates collagen-producing genes. MASH scales down the first molecule, so that inhibition is lifted on the second and third molecules, leading to stimulation of collagen production.

After discovering the signaling pathway, the scientists designed a short piece of RNA to prove the pathway behaved the way they thought it did. This RNA, called an antisense oligonucleotide (ASO), was so effective that it not only proved the viability of the pathway but also prevented liver fibrosis — too much collagen in the liver — without causing any side effects. The scientists are currently discussing licensing the ASO as a therapeutic with various pharmaceutical and biotech companies.

“All the molecules in the pathway were known, but no one knew if or how they interacted. We put the pathway together, showing each step in this intracellular signaling module. That was the science of the research. The clinical message is this ASO, which can actually block liver fibrosis,” said Jerrold Olefsky, a professor of medicine and assistant vice chancellor for integrative research at UC San Diego Health Sciences, and senior author on the paper.

The scientists carried out their investigations in organoids — tiny little livers in a dish made from three types of liver cells fed a MASH cocktail of fatty acids, fructose and sugars. They found that in normal livers, the first component of the pathway, a nuclear seven-transmembrane protein called TM7SF3, inhibits a splicing factor called hnRNPU. hnRNPU refrains from splicing out an inhibitory exon in the messenger RNA (mRNA) of TEAD1, a transcription factor that controls the genes that produce collagen. The inhibitory exon, exon 5, keeps TEAD1 from turning on the collagen-producing genes.

In the MASH-fed organoids, TM7SF3 is reduced and does not inhibit the splicing factor. The active splicing factor splices out the inhibitory exon in the transcription factor, which turns on the genes that produce collagen. This is called alternative splicing.

Furthering their investigations, they designed an ASO to keep hnRNPU from splicing out exon 5. “It had the sequence that would put it just upstream of exon 5 where hnRPU binds. The ASO prevented the splicing factor from binding to the TEAD mRNA, so it couldn’t ultimately splice it out. We got pretty much only inactive TEAD when we treated MASH mice with the ASO,” said Olefsky. With TEAD inactivated, collagen wasn’t produced. Neither was fibrosis.

“These findings show the key role of alternative splicing in shaping progression of fibrotic liver disease,” said Roi Isaac, Ph.D., assistant project scientist, Medicine, and first author on the paper.

When ASOs are administered intravenously, they enter every cell in the body, not just the target cells. Serendipitously, the scientists found that within the liver, this hnRNPU mechanism only operated in stellate cells. That made their ASO both highly effective and highly specific — the epitome of good drug design.

According to Olefsky, a quarter of the U.S. population has MASH. While the scientists’ ASO may well be an effective treatment, getting FDA approval for it would necessitate enormous clinical studies and could cost up to a billion dollars.

Olefsky and his team identified a much less common disease called primary sclerosing cholangitis, or PSC. It’s relatively rare, often fatal, and until now there were no good treatments. When the scientists tested their ASO on a mouse model of PSC, they found that their ASO almost completely blocked the development of the disease. “Getting FDA approval for PSC would be easier than getting it for MASH,” said Olefsky, “so we’re currently talking to biotech and pharma partners about licensing the ASO for PSC.”

Source: University of California, San Diego

Published on May 2, 2024

TAGGED: antisense oligonucleotide (ASO), metabolic dysfunction-associated steatohepatitis (MASH)
Admin May 2, 2024 May 2, 2024
Share This Article
Facebook Twitter Copy Link Print

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Even in Winter, Life Persists in Arctic Seas

(USCGC Healy breaking through the Bering Sea waves. Credit: Chantelle Rose/NSF)   Despite…

A Biodiversity Discovery That Was Waiting in the Wings–Wasp Wings, That Is

Wing size differences between two Nasonia wasp species are the result of…

Entertainement

Coming soon

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

Game-Changer in Emergency Medicine: New AI Test Flags Sepsis Hours Before Symptoms Worsen

By Admin

Perfumes and lotions disrupt how body protects itself from indoor air pollutants

By Admin
Health

Medical Milestone: Surgeons Perform First-Ever Human Bladder Transplant

By Admin

A Downside of Taurine: It Drives Leukemia Growth

By Admin
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Editorial Policy
  • Accessibility Statement
  • Contact US
  • Feedback
  • Advertisement
More Info
  • Newsletter
  • Beauty Lab
  • News & Perspective
  • Food & Diet
  • Health
  • Environment
  • Anatomy

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

Copyright © 2023 ScienceAbode. All Rights Reserved. Designed and Developed by Spirelab Solutions (Pvt) Ltd

Welcome Back!

Sign in to your account

Lost your password?